Novo Nordisk’s UBT251: Promising New Weight Loss Drug Shows 20% Weight Loss in Trial
The landscape of obesity treatment is rapidly evolving, and Novo Nordisk, a leading pharmaceutical company in this field, finds itself navigating both setbacks and promising developments. Just days after reporting disappointing results for one experimental drug, the company has announced encouraging findings for another, UBT251, a potential new therapy that could offer significant weight loss.
Promising Phase 2 Trial Results for UBT251
On , Novo Nordisk revealed topline data from its Phase 2 trial of UBT251. The results indicate that individuals taking UBT251 experienced weight loss of up to roughly 20% of their initial body weight after 24 weeks of treatment – a rate exceeding that typically observed with currently available medications. While still in the early stages of development, these findings position UBT251 as a potentially impactful addition to the obesity treatment pipeline.
UBT251 is being developed in collaboration with United Laboratories International Holdings Limited (TUL). It’s a “triple-agonist” drug, meaning it acts on three different hormone receptors involved in regulating appetite and metabolism: GLP-1, GIP, and glucagon. GLP-1 is the active ingredient in Novo Nordisk’s existing weight loss medications, Ozempic and Wegovy.
The Phase 2 trial, conducted in China, involved 205 participants who were either overweight or obese, with an average body mass index (BMI) of 33.1. Participants were randomly assigned to receive one of three doses of UBT251 or a placebo over a 24-week period.
The study demonstrated that all three UBT251 treatment groups experienced significantly greater weight loss compared to the placebo group, which averaged a 2% weight reduction. The highest average weight loss observed with UBT251 was 19.7%. Importantly, the drug appeared to be safe and well-tolerated, with the most common side effects being gastrointestinal in nature, and these effects generally diminished over time – a pattern similar to that seen with other GLP-1 medications.
A Potential Lifeline for Novo Nordisk
These results arrive at a crucial time for Novo Nordisk. The company has recently faced increasing competition from Eli Lilly, whose drug tirzepatide (Zepbound) has captured over 60% of the U.S. Market for obesity medications and has become the world’s top-selling medicine.
The positive UBT251 data offer a much-needed boost following a setback earlier in the week. On , Novo Nordisk reported results from a trial of CagriSema, a combination drug containing semaglutide and cagrilintide. While participants on CagriSema experienced an average weight loss of 23% over 84 weeks, the results were less favorable compared to those seen with tirzepatide, which demonstrated an average weight loss of 25.5%.
Although CagriSema remains on track for potential FDA approval this year, the trial results did not establish it as the leading obesity drug Novo Nordisk had hoped for. Following the release of these results, Novo Nordisk’s stock prices experienced a significant decline. The company has also faced other challenges in recent months, including hiring freezes and the departure of key executives, including its CEO.
With UBT251 showing promise, Novo Nordisk may have an opportunity to regain its position in the obesity treatment market. The company plans to initiate another Phase 2 trial of UBT251 this year, and TUL will soon begin a Phase 3 trial of its own.
Implications for Obesity Treatment
The development of multiple new obesity therapies, including UBT251 and Eli Lilly’s retatrutide (which has shown weight loss of up to 28% in late-stage trials), is ultimately positive news for individuals struggling with obesity. Increased treatment options provide patients with more choices, particularly for those who do not respond adequately to initial therapies. Historically, greater competition within a drug class has often led to lower prices over time, potentially increasing access to these medications.
Martin Holst Lange, executive vice president, chief scientific officer, and head of research and development at Novo Nordisk, expressed optimism about the UBT251 results, stating, “We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile.”
However, it’s important to note that the first generic versions of semaglutide are not expected to become available in the U.S. Until 2030.